Entries by angilma1

Novartis Financial Results – Q2 2024

Novartis Financial Results – Q2 2024
angilma1
Mon, 07/15/2024 – 11:49

Read more about Novartis Financial Results – Q2 2024

PrintPDF

A legacy of blood cancer innovation

A legacy of blood cancer innovation
angilma1
Fri, 05/31/2024 – 18:01

Read more about A legacy of blood cancer innovation

PrintPDF

Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML

Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
angilma1
Fri, 05/10/2024 – 10:14

Read more about Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML

PrintPDF

Novartis Financial Results – Q1 2024

Novartis Financial Results – Q1 2024
angilma1
Thu, 04/18/2024 – 09:55

Read more about Novartis Financial Results – Q1 2024

PrintPDF

Novartis Appoints Sloan Simpson as Global Head of Investor Relations

Novartis Appoints Sloan Simpson as Global Head of Investor Relations
angilma1
Thu, 02/15/2024 – 09:51

Read more about Novartis Appoints Sloan Simpson as Global Head of Investor Relations
PrintPDF

Novartis at the J.P. Morgan Healthcare Conference 2024

Novartis at the J.P. Morgan Healthcare Conference 2024
angilma1
Thu, 01/04/2024 – 15:51

Read more about Novartis at the J.P. Morgan Healthcare Conference 2024
PrintPDF

Violence against innocent people runs counter to our work to improve human health

Violence against innocent people runs counter to our work to improve human health
angilma1
Wed, 10/18/2023 – 17:37

Read more about Violence against innocent people runs counter to our work to improve human health
PrintPDF

Violence against innocent people runs counter to our work to improve human health

Violence against innocent people runs counter to our work to improve human health
angilma1
Wed, 10/18/2023 – 17:31

Read more about Violence against innocent people runs counter to our work to improve human health
PrintPDF